Servier, CTI BioPharma expand agreement to develop, commercialise Pixuvri

Servier and CTI BioPharma are expanding their existing license and development collaboration agreement for lymphoma treatment Pixuvri.

Servier will have rights to Pixuvri (pixantrone) in all markets except the US, where CTI BioPharma will retain the commercialisation privileges.

Servier will pay CTI BioPharma €12 million with the potential for CTI BioPharma to receive €76 million in additional sales and regulatory milestone payments as well as royalties on net product sales.

Pixuvri has been granted conditional marketing authorisation from the European Commission for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma (NHL).

As a specific post-authorisation requirement, Pixuvri is currently being investigated in a Phase III clinical trial, PIX306. If positive, the results from this trial will confirm the treatment’s current indication and could support broader indications.

In 2014, CTI granted Servier rights to commercialise the drug globally except in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, UK and the US.

With this expanded agreement, which provides Servier’s rights to all markets except the US, the companies will continue to work closely together to build the efficacy and safety evidence for Pixuvri and to ensure that as many eligible patients as possible are benefitting from it.

“Over the past three years, we have worked hand in hand with our partner, CTI BioPharma, to bring new treatment options to patients in Europe,” said U. Marion Schrenk, MD, Head of Therapeutic Area Oncology of Servier.

She added: “We are looking forward to leveraging our expertise in these additional markets to ensure more eligible patients have access to Pixuvri.”

Image credit: Shutterstock.com/ photo4passion.at

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...

Enrolment opens for 4D Pharma’s phase II study of live biotherapeutic in COVID-19

4D Pharma, the listed Leeds-based pharma company developing Live Biotherapeutics, has announced that its Phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients...

Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new...

Related news

CDMOs team up to simplify processes, optimise time-to-market

CDMOs Vetter and Rentschler Biopharma are collaborating to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain. With drug development...

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...